Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2023-10 · 23 (10) · e315-e322
DOI: 10.1016/j.clml.2023.07.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-10. Verfasst von Akriti G Jain und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Internal Medicine, University of Sout…. Hauptthemen laut MEDLINE: Nucleophosmin, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Moffitt Cancer Center.
Abstract (Originalsprache)
BACKGROUND: The phase III trial that led to the approval of CPX-351 for treating secondary acute myeloid leukemia (sAML) in 2017 did not study the effect of specific mutations on outcomes. METHODS: This retrospective study was done to evaluate the effect of next-generation sequencing (NGS) results at the time of best response and before allogeneic stem cell transplant (alloSCT) in patients treated with CPX-351 as frontline therapy for sAML between 2017 and 2021. RESULTS: The most common mutations seen were DNMT3A (n = 17, 29.8%), SRSF2 (n = 13, 22.8%), RUNX1 (n = 13, 22.8%), TET2 (n = 9, 15.8%), ASXL1 (n = 9, 15.8%), and BCOR (n = 9, 15.8%). Median OS (mOS) for the entire cohort was 47 months. Though 64.7% patients cleared the DNMT3A mutation, only 44.4% and 22.2% of patients cleared the TET2 and ASXL1 mutations, respectively. The mOS for patients who cleared their mutations vs. for those who did not was not significantly longer (46 vs. 30 months; P = .991). The relapse-free survival (RFS) for patients who cleared mutations was numerically longer compared to those who had persistent mutations; however, this did not reach statistical significance (44 months vs. 26 months; P = .786). CONCLUSION: This is the first study reporting NGS at best response and before alloSCT and its effect on OS and RFS. We found that OS and RFS were numerically longer among patients who cleared mutations; however, this did not reach statistical significance. In addition, alloSCT led to improved RFS irrespective of mutational clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Internal Medicine, University of South Florida, Tampa, FL.
- Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: Kendra.Sweet@moffitt.org.
Förderung
- Moffitt Cancer Center
Zitieren
APA
Jain, A. G., Ball, S., Aguirre, L. E., Tobon, K. A., Chan, O., Padron, E., Kuykendall, A., Komrokji, R., Sallman, D., Lancet, J. E., & Sweet, K. (2023). Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia, 23(10), e315-e322. https://doi.org/10.1016/j.clml.2023.07.002
Vancouver
Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, et al. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2023;23(10):e315-e322. doi:10.1016/j.clml.2023.07.002
BibTeX
@article{Jain2023,
author = {Jain, Akriti G and Ball, Somedeb and Aguirre, Luis E and Tobon, Katherine A and Chan, Onyee and Padron, Eric and Kuykendall, Andrew and Komrokji, Rami and Sallman, David and Lancet, Jeffrey E and Sweet, Kendra},
title = {Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
volume = {23},
number = {10},
pages = {e315--e322},
doi = {10.1016/j.clml.2023.07.002}
}
EUVIMED